Table 4.
Cardiac Parameters and Biomarkers
| Days Post Treatment |
|||||
|---|---|---|---|---|---|
| 0 | 8 | 14 | 28 | 90 | |
| Parameters | |||||
| LVEF | |||||
| Placebo | 29.2 ± 10.5 | 28.4 ± 6.0 | 28.1 ± 7.8 | 28.9 ± 6.8 | 31.1 ± 7.4 |
| Low dose | 27.5 ± 6.6 | 31.6 ± 8.1 | 28.2 ± 9.3 | 31.0 ± 8.0 | 26.8 ± 6.4 |
| High dose | 26.0 ± 7.5 | 29.0 ± 7.9 | 32.2 ± 11.6 | 34.9 ± 7.3 | 34.5 ± 8.0 |
| LVESV | |||||
| Placebo | 195.5 ± 120.7 | 194.6 ± 86.0 | 176.5 ± 82.3 | 192.1 ± 91.0 | 182.9 ± 95.8 |
| Low dose | 164.7 ± 107.3 | 161.2 ± 98.6 | 161.7 ± 91.8 | 167.8 ± 103.1 | 175.9 ± 102.7 |
| High dose | 151.0 ± 74.2 | 139.5 ± 64.1 | 126.9 ± 67.3 | 131.1 ± 73.4 | 127.8 ± 85.2 |
| LVEDV | |||||
| Placebo | 284.6 ± 112.7 | 269.7 ± 109.1 | 243.0 ± 94.8 | 258.8 ± 95.1 | 258.9 ± 77.6 |
| Low dose | 221.2 ± 124.0 | 227.4 ± 115.7 | 217.4 ± 99.3 | 235.1 ± 116.3 | 235.7 ± 119.9 |
| High dose | 202.8 ± 91.3 | 198.9 ± 80.8 | 180.0 ± 82.9 | 196.7 ± 100.3 | 184.2 ± 109.1 |
| HR | |||||
| Placebo | 67.9 ± 8.6 | 72.5 ± 11.1 | ND | 71.0 ± 10.6 | ND |
| Low dose | 69.9 ± 6.5 | 73.4 ± 9.1 | ND | 69.9 ± 10.2 | ND |
| High dose | 68.4 ± 13.2 | 67.5 ± 9.6 | ND | 69.6 ± 9.9 | ND |
| MAP | |||||
| Placebo | 80.4 ± 6.9 | 82.2 ± 6.4 | ND | 84.5 ± 5.2 | ND |
| Low dose | 79.6 ± 10.9 | 86.1 ± 13.5 | ND | 79.0 ± 10.2 | ND |
| High dose | 73.1 ± 7.5 | 89.8 ± 9.7 | ND | 87.0 ± 10.0 | ND |
| SBP | |||||
| Placebo | 119.6 ± 12.0 | 109.6 ± 8.6 | ND | 112.1 ± 10.4 | ND |
| Low dose | 115.9 ± 18.8 | 116.8 ± 20.8 | ND | 107.9 ± 12.9 | ND |
| High dose | 114.2 ± 14.3 | 117.1 ± 11.4 | ND | 115.5 ± 11.8 | ND |
| DBP | |||||
| Placebo | 71.1 ± 4.7 | 68.5 ± 7.1 | ND | 70.6 ± 4.3 | ND |
| Low dose | 65.9 ± 9.1 | 70.8 ± 12.9 | ND | 64.5 ± 10.4 | ND |
| High dose | 70.9 ± 10.1 | 76.1 ± 9.7 | ND | 72.7 ± 10.8 | ND |
| Biomarkers | |||||
| BNP (pg/ML) | |||||
| Placebo | 230 (108, 299; 191) | 202 (89, 317; 228) | ND | 177 (115, 237; 122) | ND |
| Low dose | 279 (140, 432; 292) | 332 (188, 447; 258) | ND | 267 (116, 405; 289) | ND |
| High dose | 108 (80, 301; 221) | 230 (185, 619; 434) | ND | 162 (74, 342; 268) | ND |
| NT-proBNP (fmol/ML) | |||||
| Placebo | 898 (527, 1,495; 968) | 877 (536, 1,467; 931) | ND | 800 (564, 1,044; 480) | ND |
| Low dose | 831 (513, 947; 434) | 843 (658, 937; 279) | ND | 910 (508, 1,161; 653) | ND |
| High dose | 552 (310, 1,134; 824) | 1193 (702, 1,598; 896) | ND | 653 (328, 1,194; 866) | ND |
| Tn-I (ng/l) | |||||
| Placebo | 20 (20, 30; 10) | 20 (10, 30; 20) | ND | 10 (10, 30; 20) | ND |
| Low dose | 10 (10, 10; 0) | 10 (10, 15; 5) | ND | 10 (10, 10; 0) | ND |
| High dose | 10 (10, 20; 10) | 10 (10, 25; 15) | ND | 10 (10, 30; 20) | ND |
Values are mean ± SD or median (25th, 75th; interquartile range).
DBP = diastolic blood pressure; HR = heart rate; LVEDV = left ventricular end diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end systolic volume; MAP = mean arterial pressure; ND = not done; NT-proBNP = N-terminal pro-B-type natriuretic peptide; SBP = systolic blood pressure; Tn-I = troponin I.